CIK 0001937653 · Non-accelerated filer<br>Smaller reporting company
Zymeworks Inc.
Sign in to watch- Ticker
- ZYME
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 883099146
- Phone
- 302-274-8744
- Business address
- 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709
- Former names
- Zymeworks Delaware Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $357,557
- in 1 filing
Net −$357,557. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-05 | Moore Paul Andrew Chief Scientific Officer | Option exercise | +17,168 | 40,501 | ||
| 2026-01-05 | Moore Paul Andrew Chief Scientific Officer | Sale | −9,289 | $25.10 | $233K | 31,212 |
| 2026-01-05 | Moore Paul Andrew Chief Scientific Officer | Option exercise | +20,000 | 51,212 | ||
| 2026-01-05 | Moore Paul Andrew Chief Scientific Officer | Sale | −10,821 | $25.10 | $272K | 40,391 |
| 2026-01-05 | Moore Paul Andrew Chief Scientific Officer | Option exercise · Restricted Stock Unit | −17,168 | 0 | ||
| 2026-01-05 | Moore Paul Andrew Chief Scientific Officer | Option exercise · Restricted Stock Unit | −20,000 | 20,000 | ||
| 2025-12-22 | Galbraith Kenneth Chair & CEO | Option exercise | +100,000 | 180,803 | ||
| 2025-12-22 | Galbraith Kenneth Chair & CEO | Sale | −47,528 | $27.02 | $1.3M | 133,275 |
| 2025-12-22 | Galbraith Kenneth Chair & CEO | Option exercise · Restricted Stock Unit | −100,000 | 0 | ||
| 2025-08-12 | Ciongoli Gregory Austin Director | Grant or award | +415,000 | $12.02 | $5.0M | 488,500 |
| 2025-08-11 | Ciongoli Gregory Austin Director | Grant or award · Stock Option (Right to Buy) | +62,000 | 62,000 | ||
| 2025-08-11 | Landry Robert E Director | Grant or award · Stock Option (Right to Buy) | +62,000 | 62,000 | ||
| 2025-06-26 | EcoR1 Capital, LLC Director | Option exercise | +5,086,480 | $0.00 | $509 | 22,970,388 |
| 2025-06-26 | EcoR1 Capital, LLC Director | Shares withheld for taxes | −41 | $12.71 | $521 | 22,970,388 |
| 2025-06-26 | EcoR1 Capital, LLC Director | Option exercise · Pre-Funded Warrants (right to acquire) | −5,086,521 | 0 | ||
| 2025-05-19 | EcoR1 Capital, LLC Director | Purchase | +5,919 | $11.78 | $70K | 17,883,908 |
| 2025-05-15 | EcoR1 Capital, LLC Director | Purchase | +49,502 | $11.43 | $566K | 17,877,989 |
| 2025-04-17 | EcoR1 Capital, LLC Director | Purchase | +54,760 | $11.52 | $631K | 17,828,487 |
| 2025-04-16 | EcoR1 Capital, LLC Director | Purchase | +73,953 | $11.16 | $826K | 17,773,727 |
| 2025-04-04 | EcoR1 Capital, LLC Director | Purchase | +196,438 | $11.17 | $2.2M | 17,699,774 |
Page 4 of 12 · 224 trades